A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Fardin, Paolo ^a   Barla, Annalisa ^b   Mosci, Sofia ^b   Rosasco, Lorenzo ^b,c   Verri, Alessandro ^b   Versteeg, Rogier ^d   Caron, Huib N ^d   Molenaar, Jan J ^d   Øra, Ingrid ^d   Eva, Alessandra ^a   Puppo, Maura ^a   Varesio, Luigi ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; TRANSCRIPTOME;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; NEUROBLASTOMA; NEUROBLASTOMA CELL; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PREDICTION; PRESCHOOL CHILD; PROGNOSIS; PROTO ONCOGENE; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SYSTEM ANALYSIS; CELL HYPOXIA; DNA MICROARRAY; GENETICS; INFANT; ONCOGENE MYC; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

CELL HYPOXIA; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENES, MYC; HUMANS; INFANT; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TREATMENT OUTCOME;

EID: 77954419844     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-185     Document Type: Article

References (91)

1. De Preter K, Vandesompele J, Heimann P, Yigit N, Beckman S, Schramm A, Eggert A, Stallings R, Benoit Y, Renard M, et al. Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biology 2006, 7:R84. 10.1186/gb-2006-7-9-r84, 1794547, 16989664.
2. Thiele CJ. Neuroblastoma. Human Cell Culture 1999, 21-22. London: Kluwer Academic, Master JRW, Palsson B.
3. Maris J, Hogarty M, Bagatell R, Cohn S. Neuroblastoma. Lancet 2007, 369:2106-2120. 10.1016/S0140-6736(07)60983-0, 17586306.
4. Weinstein J, Katzenstein H, Cohn S. Advances in the diagnosis and treatment of neuroblastoma. Oncologist 2003, 8:278-292. 10.1634/theoncologist.8-3-278, 12773750.
5. Bordow S, Norris M, Haber P, Marshall G, Haber M. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. Journal of clinical oncology 1998, 16:3286-3294.
6. van Noesel MM, Versteeg R. Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'. Gene 2004, 325:1-15. 10.1016/j.gene.2003.09.042, 14697505.
7. Boon K, Caron H, van Asperen R, Valentijn L, Hermus M, van Sluis P, Roobeek I, Weis I, Voute P, Schwab M, et al. N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J 2001, 20:1383-1393. 10.1093/emboj/20.6.1383, 145518, 11250904.
8. Meitar D, Crawford S, Rademaker A, Cohn S. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. Journal of clinical oncology 1996, 14:405-414.
9. Puppo M, Pastorino S, Melillo G, Pezzolo A, Varesio L, Bosco MC. Induction of apoptosis by flavopiridol in human neuroblastoma cells is enhanced under hypoxia and associated with N-myc proto-oncogene down-regulation. Clin Cancer Res 2004, 10:8704-8719. 10.1158/1078-0432.CCR-03-0422, 15623656.
10. Puppo M, Battaglia F, Ottaviano C, Delfino S, Ribatti D, Varesio L, Bosco M. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha. Mol Cancer Ther 2008, 7:1974-1984. 10.1158/1535-7163.MCT-07-2059, 18645007.
11. Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S, et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 2002, 99:11399-11404. 10.1073/pnas.172398399, 123268, 12177446.
12. Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 2009, 19:12-16. 10.1016/j.semcancer.2008.11.009, 19114105.
13. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394:485-490. 10.1038/28867, 9697772.
14. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47. 10.1038/nrc704, 11902584.
15. Bosco MC, Puppo M, Santangelo C, Anfosso L, Pfeffer U, Fardin P, Battaglia F, Varesio L. Hypoxia modifies the transcriptome of primary human monocytes: modulation of novel immune-related genes and identification of CC-chemokine ligand 20 as a new hypoxia-inducible gene. J Immunol 2006, 177:1941-1955.
16. Bosco MC, Puppo M, Blengio F, Fraone T, Cappello P, Giovarelli M, Varesio L. Monocytes and dendritic cells in a hypoxic environment: Spotlights on chemotaxis and migration. Immunobiology 2008, 213:733-749. 10.1016/j.imbio.2008.07.031, 18926289.
17. Carta L, Pastorino S, Melillo G, Bosco M, Massazza S, Varesio L. Engineering of macrophages to produce IFN-gamma in response to hypoxia. J Immunol 2001, 166:5374-5380.
18. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000, 157:411-421. 1850121, 10934146.
19. Melillo G, Musso T, Sica A, Taylor L, Cox G, Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J Exp Med 1995, 182:1683-1693. 10.1084/jem.182.6.1683, 2192245, 7500013.
20. Chan DA, Giaccia AJ. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 2007, 26:333-339. 10.1007/s10555-007-9063-1, 17458506.
21. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008, 15:678-685. 10.1038/cdd.2008.21, 18259193.
22. Matthay K, Villablanca J, Seeger R, Stram D, Harris R, Ramsay N, Swift P, Shimada H, Black C, Brodeur GM, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999, 341:1165-1173. 10.1056/NEJM199910143411601, 10519894.
23. Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, Nilsson H, Pietras A, Vallon-Christersson J, Borg A, Gradin K, et al. Recruitment of HIF-1 alpha and HIF-2 alpha to common target genes is differentially regulated in neuroblastoma: HIF-2 alpha promotes an aggressive phenotype. Cancer Cell 2006, 10:413-423. 10.1016/j.ccr.2006.08.026, 17097563.
24. Poomthavorn P, Wong SH, Higgins S, Werther GA, Russo VC. Activation of a prometastatic gene expression program in hypoxic neuroblastoma cells. Endocr Relat Cancer 2009, 16:991-1004. 10.1677/ERC-08-0340, 19423615.
25. Edsjo A, Holmquist L, Pahlman S. Neuroblastoma as an experimental model for neuronal differentiation and hypoxia-induced tumor cell dedifferentiation. Semin Cancer Biol 2007, 17:248-256. 10.1016/j.semcancer.2006.04.005, 16828305.
26. Zou H, Hastie T. Regularization and variable selection via the elastic net. Journal of the Royal Statistical Society Series B-Statistical Methodology 2005, 67:301-320.
27. De Mol C, Mosci S, Traskine M, Verri A. A Regularized Method for Selecting Nested Groups of Relevant Genes from Microarray Data. Journal of Computational Biology 2009, 16:677-690. 10.1089/cmb.2008.0171, 19432538.
28. Fardin P, Barla A, Mosci S, Rosasco L, Verri A, Varesio L. The l1-l2 regularization framework unmasks the hypoxia signature hidden in the transcriptome of a set of heterogeneous neuroblastoma cell lines. BMC Genomics 2009, 10:474. 10.1186/1471-2164-10-474, 2768750, 19832978.
29. Ricciardi A, Elia AR, Cappello P, Puppo M, Vanni C, Fardin P, Eva A, Munroe D, Wu X, Giovarelli M, et al. Transcriptome of hypoxic immature dendritic cells: modulation of chemokine/receptor expression. Mol Cancer Res 2008, 6:175-185. 10.1158/1541-7786.MCR-07-0391, 18314479.
30. Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H, Shah KA, Cox GJ, Corbridge RJ, Homer JJ, et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 2007, 67:3441-3449. 10.1158/0008-5472.CAN-06-3322, 17409455.
31. Buffa FM, Harris AL, West CM, Miller CJ. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. British Journal of Cancer 2010, 102:428-435. 10.1038/sj.bjc.6605450, 20087356.
32. Hu ZY, Fan C, Livasy C, He XP, Oh DS, Ewend MG, Carey LA, Subramanian S, West R, Ikpatt F, et al. A compact VEGF signature associated with distant metastases and poor outcomes. Bmc Medicine 2009, 7.
33. Seigneuric R, Starmans MHW, Fung G, Krishnapuram B, Nuyten DSA, van Erk A, Magagnin MG, Rouschop KM, Krishnan S, Rao RB, et al. Impact of supervised gene signatures of early hypoxia on patient survival. Radiotherapy and Oncology 2007, 83:374-382. 10.1016/j.radonc.2007.05.002, 17532074.
34. Berthold F, Hero B, Breu H, Christiansen H, Erttmann R, Gnekow A, Herrmann F, Klingebiel T, Lampert F, Muller-Weihrich S, et al. The recurrence patterns of stages I, II and III neuroblastoma: experience with 77 relapsing patients. Ann Oncol 1996, 7:183-187.
35. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-Dale AL, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006, 3:e47. 10.1371/journal.pmed.0030047, 1334226,1334226, 16417408.
36. Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, Schleiermacher G, Speleman F, Spitz R, London WB, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. British Journal of Cancer 2009, 100:1471-1482. 10.1038/sj.bjc.6605014, 2694415, 19401703.
37. Brown JM, William WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004, 4:437-447. 10.1038/nrc1367, 15170446.
38. Semenza G. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732. 10.1038/nrc1187, 13130303.
39. Jogi A, Ora I, Nilsson H, Lindeheim A, Makino Y, Poellinger L, Axelson H, Pahlman S. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. PNAS 2002, 99:7021-7026. 10.1073/pnas.102660199, 124521, 12011461.
40. Pietras A, Gisselsson D, Ora I, Noguera R, Beckman S, Navarro S, Pahlman S. High levels of HIF-2 alpha highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche. Journal of Pathology 2008, 214:482-488. 10.1002/path.2304, 18189331.
41. Forristal CE, Wright KL, Hanley NA, Oreffo ROC, Houghton FD. Hypoxia inducible factors regulate pluripotency and proliferation in human embryonic stem cells cultured at reduced oxygen tensions. Reproduction 2010, 139:85-97. 10.1530/REP-09-0300, 2791494, 19755485.
42. Pietras A, Hansford LM, Johnsson AS, Bridges E, Sjolund J, Gisselsson D, Rehn M, Beckman S, Noguera R, Navarro S, et al. HIF-2 alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. PNAS 2009, 106:16805-16810. 10.1073/pnas.0904606106, 2745331, 19805377.
43. Wenger R, Stiehl D, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005, 2005:re12. 10.1126/stke.3062005re12, 16234508.
44. Lofstedt T, Fredlund E, Holmquist-Mengelbier L, Pietras A, Ovenberger M, Poellinger L, Pahlman S. Hypoxia inducible factor-2 alpha in cancer. Cell Cycle 2007, 6:919-926.
45. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-1 alpha-versus HIF-2 alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-1, or loss of von Hippel-Lindau function: Implications for targeting the HIF pathway. Cancer Res 2006, 66:6264-6270. 10.1158/0008-5472.CAN-05-2519, 16778202.
46. Favier J, Lapointe S, Maliba R, Sirois MG. HIF2 alpha reduces growth rate but promotes angiogenesis in a mouse model of neuroblastoma. BMC Cancer 2007, 7. 10.1186/1471-2407-7-139, 1950713, 17655754.
47. Noguera R, Fredlund E, Piqueras M, Pietras A, Beckman S, Navarro S, Pahlman S. HIF-1 alpha and HIF-2 alpha Are Differentially Regulated In vivo in Neuroblastoma: High HIF-1 alpha Correlates Negatively to Advanced Clinical Stage and Tumor Vascularization. Clinical Cancer Research 2009, 15:7130-7136. 10.1158/1078-0432.CCR-09-0223, 19903792.
48. Fredlund E, Ringner M, Maris JM, Pahlman S. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. PNAS 2008, 105:14094-14099. 10.1073/pnas.0804455105, 2544584, 18780787.
49. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985, 313:1111-1116.
50. Schmidt ML, Lukens JN, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, Stram DO, Perez C, Haase GM, Matthay KK. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol 2000, 18:1260-1268.
51. Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, Matthay K, Buckley J, Ortega A, Seeger R. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006, 98:1193-1203. 10.1093/jnci/djj330, 16954472.
52. Wei J, Greer B, Westermann F, Steinberg S, Son C, Chen Q, Whiteford C, Bilke S, Krasnoselsky A, Cenacchi N, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004, 64:6883-6891. 10.1158/0008-5472.CAN-04-0695, 1298184, 15466177.
53. Schramm A, Vandesompele J, Schulte JH, Dreesmann S, Kaderali L, Brors B, Eils R, Speleman F, Eggert A. Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome. Clinical Cancer Research 2007, 13:1459-1465. 10.1158/1078-0432.CCR-06-2032, 17332289.
54. Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A, Hirata T, Kubo H, Goto T, Yamada S. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005, 7:337-350. 10.1016/j.ccr.2005.03.019, 15837623.
55. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, Ernestus K, Konig R, Haas S, Eils R, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. Journal of clinical oncology 2006, 24:5070-5078. 10.1200/JCO.2006.06.1879, 17075126.
56. Chen QR, Song YK, Wei JS, Bilke S, Asgharzadeh S, Seeger RC, Khan J. An integrated cross-platform prognosis study on neuroblastoma patients. Genomics 2008, 92:195-203. 10.1016/j.ygeno.2008.05.014, 2562635, 18598751.
57. Oberthuer A, Kaderali L, Kahlert Y, Hero B, Westermann F, Berthold F, Brors B, Eils R, Fischer M. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR. Clin Cancer Res 2008, 14:6590-6601. 10.1158/1078-0432.CCR-07-4377, 18927300.
58. Schramm A, Mierswa I, Kaderali L, Morik K, Eggert A, Schulte JH. Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction. Cancer Lett 2009, 282:55-62. 10.1016/j.canlet.2009.02.052, 19349112.
59. Fischer M, Oberthuer A, Brors B, Kahlert Y, Skowron M, Voth H, Warnat P, Ernestus K, Hero B, Berthold F. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clinical Cancer Research 2006, 12:5118-5128. 10.1158/1078-0432.CCR-06-0985, 16951229.
60. Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo S, Scaruffi P, Tonini GP, et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009, 10:663-671. 10.1016/S1470-2045(09)70154-8, 19515614.
61. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004, 9(Suppl 5):10-17. 10.1634/theoncologist.9-90005-10, 15591418.
62. Haupt R, Garaventa A, Gambini C, Parodi S, Cangemi G, Casale F, Viscardi E, Bianchi M, Prete A, Jenkner A, et al. Improved survival of children with neuroblastoma between 1979 and 2005: a report of the Italian Neuroblastoma Registry. J Clin Oncol 2010, 28:2331-2338. 10.1200/JCO.2009.24.8351, 20351331.
63. Ikematsu S, Nakagawara A, Nakamura Y, Ohira M, Shinjo M, Kishida S, Kadomatsu K. Plasma midkine level is a prognostic factor for human neuroblastoma. Cancer Sci 2008, 99:2070-2074.
64. Granchi D, Garaventa A, Amato I, Paolucci P, Baldini N. Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma. Int J Cancer 2006, 119:146-151. 10.1002/ijc.21783, 16450378.
65. Hewitson KS, Schofield CJ. The HIF pathway as a therapeutic target. Drug Discov Today 2004, 9:704-711. 10.1016/S1359-6446(04)03202-7, 15341784.
66. Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 2007, 26:341-352. 10.1007/s10555-007-9059-x, 17415529.
67. Zhang LB, Smith K, Chong AL, Stempak D, Yeger H, Marrano P, Thorner PS, Irwin MS, Kaplan DR, Baruchel S. In Vivo Antitumor and Antimetastatic Activity of Sunitinib in Preclinical Neuroblastoma Mouse Model. Neoplasia 2009, 11:426-435. 2671855, 19412427.
68. Schmidt C. Why do tumors become resistant to antiangiogenesis drugs?. J Natl Cancer Inst 2009, 101:1530-1532. 10.1093/jnci/djp425, 19880813.
69. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231. 10.1016/j.ccr.2009.01.027, 2874829, 19249680.
70. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239. 10.1016/j.ccr.2009.01.021, 19249681.
71. Semenza G. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001, 7:345-350. 10.1016/S1471-4914(01)02090-1, 11516994.
72. Murata M, Yudo K, Nakamura H, Chiha J, Okamoto K, Suematsu N, Nishioka K, Beppu M, Inoue K, Kato T, et al. Hypoxia Upregulates the Expression of Angiopoietin-Like-4 in Human Articular Chondrocytes: Role of Angiopoietin-Like-4 in the Expression of Matrix Metalloproteinases and Cartilage Degradation. Journal of Orthopaedic Research 2009, 27:50-57. 10.1002/jor.20703, 18634015.
73. Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ. An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res 2009, 37:4587-4602. 10.1093/nar/gkp425, 2724271, 19491311.
74. Yoon DY, Buchler P, Saarikoski ST, Hines OJ, Reber HA, Hankinson O. Identification of genes differentially induced by hypoxia in pancreatic cancer cells. Biochem Biophys Res Commun 2001, 288:882-886. 10.1006/bbrc.2001.5867, 11688991.
75. Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouyssegur J, Mazure NM. Hypoxia-Induced Autophagy Is Mediated through Hypoxia-Inducible Factor Induction of BNIP3 and BNIP3L via Their BH3 Domains. Molecular and Cellular Biology 2009, 29:2570-2581. 10.1128/MCB.00166-09, 2682037, 19273585.
76. Zhong XP, Wang D, Zhang YB, Gui JF. Identification and characterization of hypoxia-induced genes in Carassius auratus blastulae embryonic cells using suppression subtractive hybridization. Comp Biochem Physiol B Biochem Mol Biol 2009, 152:161-170. 10.1016/j.cbpb.2008.10.013, 19068236.
77. Lee M, Kim J, Suk K, Park J. Identification of the hypoxia-inducible factor 1 alpha-responsive HGTD-P gene as a mediator in the mitochondrial apoptotic pathway. Mol Cell Biol 2004, 24:3918-3927. 10.1128/MCB.24.9.3918-3927.2004, 387743, 15082785.
78. Patiar S, Harris AL. Role of hypoxia-inducible factor-1alpha as a cancer therapy target. Endocr Relat Cancer 2006, 13(Suppl 1):S61-S75. 10.1677/erc.1.01290, 17259560.
79. Metzen E. Enzyme substrate recognition in oxygen sensing: how the HIF trap snaps. Biochem J 2007, 408:e5-e6. 10.1042/BJ20071306, 2267343, 17990984.
80. Kang SG, Brown AL, Chung JH. Oxygen tension regulates the stability of insulin receptor substrate-1 (IRS-1) through caspase-mediated cleavage. J Biol Chem 2007, 282:6090-6097. 10.1074/jbc.M610659200, 17179152.
81. Le Jan S, Le Meur N, Cazes A, Philippe J, Le Cunff M, Leger J, Corvol P, Germain S. Characterization of the expression of the hypoxia-induced genes neuritin, TXNIP and IGFBP3 in cancer. FEBS Lett 2006, 580:3395-3400. 10.1016/j.febslet.2006.05.011, 16723126.
82. Wellmann S, Bettkober M, Zelmer A, Seeger K, Faigle M, Eltzschig HK, Buhrer C. Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. Biochem Biophys Res Commun 2008, 372:892-897. 10.1016/j.bbrc.2008.05.150, 18538129.
83. Corn PG, Ricci MS, Scata KA, Arsham AM, Simon MC, Dicker DT, El Deiry WS. Mxi1 is induced by hypoxia in a HIF-1-dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol Ther 2005, 4:1285-1294.
84. Sibold S, Roh V, Keogh A, Studer P, Tiffon C, Angst E, Vorburger SA, Weimann R, Candinas D, Stroka D. Hypoxia increases cytoplasmic expression of NDRG1, but is insufficient for its membrane localization in human hepatocellular carcinoma. FEBS Lett 2007, 581:989-994. 10.1016/j.febslet.2007.01.080, 17316623.
85. Hofbauer KH, Gess B, Lohaus C, Meyer HE, Katschinski D, Kurtz A. Oxygen tension regulates the expression of a group of procollagen hydroxylases. Eur J Biochem 2003, 270:4515-4522. 10.1046/j.1432-1033.2003.03846.x, 14622280.
86. Minchenko O, Opentanova I, Minchenko D, Ogura T, Esumi H. Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 gene via hypoxia-inducible factor-1alpha activation. FEBS Lett 2004, 576:14-20. 10.1016/j.febslet.2004.08.053, 15474002.
87. Li H, Ko HP, Whitlock JP. Induction of phosphoglycerate kinase 1 gene expression by hypoxia. Roles of Arnt and HIF1alpha. J Biol Chem 1996, 271:21262-21267. 10.1074/jbc.271.35.21262, 8702901.
88. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994, 269:23757-23763.
89. Zhang JZ, Behrooz A, Ismail-Beigi F. Regulation of glucose transport by hypoxia. Am J Kidney Dis 1999, 34:189-202. 10.1016/S0272-6386(99)70131-9, 10401038.
90. Niitsu Y, Hori O, Yamaguchi A, Bando Y, Ozawa K, Tamatani M, Ogawa S, Tohyama M. Exposure of cultured primary rat astrocytes to hypoxia results in intracellular glucose depletion and induction of glycolytic enzymes. Brain Res Mol Brain Res 1999, 74:26-34. 10.1016/S0169-328X(99)00245-4, 10640673.
91. Murat A, Migliavacca E, Hussain SF, Heimberger AB, Desbaillets I, Hamou MF, Ruegg C, Stupp R, Delorenzi M, Hegi ME. Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS ONE 2009, 4:e5947. 10.1371/journal.pone.0005947, 2694268, 19536297.